Novo Nordisk introduces NovoRapid PumpCart insulin pump

Today, Novo Nordisk launches NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains NovoRapid® (insulin aspart) – a rapid-acting insulin from Novo Nordisk – is expected to make insulin pump therapy more convenient for people with diabetes and their care staff. The 1.6 ml cartridge is developed in a non-exclusive partnership between Roche Diabetes Care and Novo Nordisk and is compatible with the new Accu-Chek®Insight insulin pump therapy system from Roche Diabetes Care.

“One of the challenges in operating a traditional pump lies in the manual filling of the insulin reservoir, a procedure with multiple steps, which can often be perceived as a complex and time-consuming process by patients and healthcare professionals alike,” commented Dr Parth Narendran, clinical senior lecturer and honorary consultant in medicine at the University of Birmingham.

He continued: “This can be a difficult hurdle to overcome when starting on insulin pump therapy, and is exacerbated by the extensive amount of time needed by healthcare staff to provide the necessary support during pump initiation. A simpler process could address this issue and deliver tangible benefits for those patients who rely on insulin pump therapy every day to manage their diabetes.”

Compared to multiple daily injections, insulin pumps can provide greater flexibility of lifestyle and potentially tighter blood glucose control without an increased risk of hypoglycaemia.

“This can provide benefits to certain patients,” explained Dr Mark Evans, lecturer and honorary consultant in medicine at the University of Cambridge. “In Europe, we’ve seen a slow but steady increase in insulin pump therapy uptake in recent years, but there is still room for improvement; in the United Kingdom pumps are currently used by 19% of children and 6% of adults with type 1 diabetes.”

NovoRapid® PumpCart® is being launched in the UK, Sweden and Austria today and will be made available in more European countries throughout 2015 and 2016. The Accu-Chek® Insight insulin pump therapy system has been launched in Austria in the first half of this year and is being launched in the UK today, with other European markets following throughout 2015.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Novo Nordisk. (2019, June 18). Novo Nordisk introduces NovoRapid PumpCart insulin pump. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20141103/Novo-Nordisk-introduces-NovoRapid-PumpCart-insulin-pump.aspx.

  • MLA

    Novo Nordisk. "Novo Nordisk introduces NovoRapid PumpCart insulin pump". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20141103/Novo-Nordisk-introduces-NovoRapid-PumpCart-insulin-pump.aspx>.

  • Chicago

    Novo Nordisk. "Novo Nordisk introduces NovoRapid PumpCart insulin pump". News-Medical. https://www.news-medical.net/news/20141103/Novo-Nordisk-introduces-NovoRapid-PumpCart-insulin-pump.aspx. (accessed November 21, 2024).

  • Harvard

    Novo Nordisk. 2019. Novo Nordisk introduces NovoRapid PumpCart insulin pump. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20141103/Novo-Nordisk-introduces-NovoRapid-PumpCart-insulin-pump.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Addressing social and cultural factors is key to reducing burden of type 2 diabetes